ISOSULFAN BLUE INNER SALT

Details

Stereochemistry	ACHIRAL
Molecular Formula	C27H32N2O6S2
Molecular Weight	544.683
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(C=C2)=[N+](CC)CC)C3=C(C=CC(=C3)S(O)(=O)=O)S([O-])(=O)=O

InChI

InChIKey=YFKDCGWIINMRQY-UHFFFAOYSA-N

InChI=1S/C27H32N2O6S2/c1-5-28(6-2)22-13-9-20(10-14-22)27(21-11-15-23(16-12-21)29(7-3)8-4)25-19-24(36(30,31)32)17-18-26(25)37(33,34)35/h9-19H,5-8H2,1-4H3,(H-,30,31,32,33,34,35)

HIDE SMILES / InChI

Molecular Formula	C27H32N2O6S2
Molecular Weight	544.683
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42f2d62a-c7f2-4706-87bc-64f3e72d63a9

Isosulfan Blue is a synthetic visual lymphatic imaging agent. Injected into the periphery of the tumor site, isosulfan blue localizes to the lymphatic system and aids in the surgical identification of tumor sentinel nodes which stain blue. The chemical name of isosulfan blue is N-[4-[[4-(diethylamino)phenyl] (2,5-disulfophenyl) methylene]-2,5-cyclohexadien-1-ylidene]-N-ethylethanaminium hydroxide, inner salt, sodium salt. Isosulfan blue is a greenish blue color hygroscopic powder. Isosulfan blue injection 1% is a contrast agent for the delineation of lymphatic vessels. Isosulfan blue injection 1% upon subcutaneous administration, delineates lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities.

Approval Year

Conditions

Condition	Modality	Targets	Highest Phase	Product
Lymphatic vessel delineation 2 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42f2d62a-c7f2-4706-87bc-64f3e72d63a9	Diagnostic		Approved 8429	ISOSULFAN BLUE Approved Use Lymphatic Vessel Delineation

C_max

Value	Dose	Co-administered	Analyte	Population
11.03 mg/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29141490/	938 mmol/kg single, subcutaneous dose: 938 mmol/kg route of administration: Subcutaneous experiment type: SINGLE co-administered:		ISOSULFAN BLUE plasma	Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
2.9 mg × h/kg EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29141490/	938 mmol/kg single, subcutaneous dose: 938 mmol/kg route of administration: Subcutaneous experiment type: SINGLE co-administered:		ISOSULFAN BLUE plasma	Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.14 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/29141490/	938 mmol/kg single, subcutaneous dose: 938 mmol/kg route of administration: Subcutaneous experiment type: SINGLE co-administered:		ISOSULFAN BLUE plasma	Mus musculus population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
99% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unknown, subcutaneous		ISOSULFAN BLUE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	Other AEs: Hypersensitivity, Respiratory distress... Other AEs: Hypersensitivity (2%) Respiratory distress (grade 4) Shock (grade 4) Angioedema (grade 4) Urticaria (grade 4) Pruritus (grade 4) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf

AEs

AE	Significance	Dose	Population
Hypersensitivity	2%	3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf
Angioedema	grade 4	3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf
Pruritus	grade 4	3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf
Respiratory distress	grade 4	3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf
Shock	grade 4	3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf
Urticaria	grade 4	3 mL single, subcutaneous (max) Studied dose Dose: 3 mL Route: subcutaneous Route: single Dose: 3 mL Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf	unhealthy Health Status: unhealthy Condition: lymphedema of the extremities Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/018310s011lbl.pdf

Sourcing

Vendor/Aggregator	ID	URL
Accela ChemBio Inc	SY238240
AstaTech	FD10698
BLD Pharm	BD01293511	http://www.bldpharm.com/products/748080-29-7.html
Compound Cloud	4695
Compound Cloud	50108
MolPort	MolPort-046-936-648
MuseChem	M015871
PI Chemicals	PI-46531
ZINC	ZINC000003873832	http://zinc15.docking.org/substances/ZINC000003873832
eMolecules	178517649
eMolecules	195048656

Patents

Sample Use Guides

In Vivo Use Guide

Isosulfan blue injection 1% is to be administered subcutaneously, one-half (1/2) mL into three interdigital spaces of each extremity per study. A maximum dose of 3 mL isosulfan blue is, therefore, injected.

Route of Administration: Other

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 21:31:10 GMT 2023` Edited by `admin` on `Fri Dec 15 21:31:10 GMT 2023`
Record UNII	NS6Q291771
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ISOSULFAN BLUE INNER SALT

Common Name

English

ETHANAMINIUM, N-(4-((4-(DIETHYLAMINO)PHENYL)(2,5-DISULFOPHENYL)METHYLENE)-2,5-CYCLOHEXADIEN-1-YLIDENE)-N-ETHYL-, INNER SALT

Common Name

English

Code System Code Type Description

CAS

748080-29-7